IMMUNOREGULATORY FUNCTIONS OF THE ISOFORMS OF CD44

CD44 异构体的免疫调节功能

基本信息

  • 批准号:
    2077474
  • 负责人:
  • 金额:
    $ 5.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1993
  • 资助国家:
    美国
  • 起止时间:
    1993-09-15 至 1998-08-31
  • 项目状态:
    已结题

项目摘要

The objective of this proposal is to enable the applicant to develop expertise as an independent medical research scientist in the fields of basic immunology and autoimmunemediated connective tissue disease. The applicant proposes to accomplish this objective in two phases over a five year period. Phase l will be devoted primarily to didactic learning and the acquisition of laboratory skills necessary to carry out the research proposed in phase Il. The specific aims of phase I are the following: A. To undergo rigorous training within the Graduate School in the Dept. of lmmunology, Duke University, to earn a doctoral degree (Ph.D.) in lmmunology. In order to attain this goal, the applicant will begin graduate school in Sept. 1993 and has selected coursework that will be accomplished during this phase. B. To attain laboratory expertise in the area of lymphocyte and monocyte function, especially with regards to the role that these cells play in the abnormal immune response of diseases such as rheumatoid arthritis. In order to attain this goal, work will be carried out on the transmembrane proteoglycan CD44. CD44 and its ligand hyaluronan (HA) are involved in leukocyte cell surface interactions that modulate the immune response. Differential expression of the various isoforms of CD44 on leukocytes and production of a soluble form of CD44 likely lead to the ability of CD44 to modulate CD3-T cell receptor mediated T lymphocyte activation and to regulate cell surface binding of HA to leukocytes. The specific aims of this part of phase l are: 1. To characterize the CD44 Isoforms present on human peripheral blood T lymphocytes, B lymphocytes and monocytes especially with regards to the molecular characteristics that allow binding of HA to CD44. 2. Characterize monoclonal and polyclonal antibody reagents that bind to specific isoforms and/or functional epitopes of CD44 molecules. The intensive research experience in phase II will utilize the reagents and knowledge gained about the role of the different CD44 isoforms in T lymphocyte activation and their ability to bind HA to study the regulation of CD44 expression and to study what role CD44 plays in the pathogenesis of rheumatoid arthritis. The specific aims of phase II are: 1. To define the extracellular signals and the intracellular molecular events that regulate CD44 binding to HA and enhance TCR-mediated T cell activation. 2. To define the regulatory role of CD44 in the immune response and determine the immune-mediated functions of the individual CD44 isoforms. 3. Examine the abnormal immune response in rheumatoid arthritis utilizing the antibody reagents developed in phase land the knowledge gained about the regulation of CD44.
本建议书的目的是使申请人能够发展 作为一名独立的医学研究科学家, 基础免疫学和自身免疫介导的结缔组织病。的 申请人建议在五年内分两个阶段实现这一目标。 年期间。第一阶段将主要致力于教学式学习, 获得进行研究所需的实验室技能 在第二阶段提出。 第一阶段的具体目标如下:经过严格 本系研究生院内的培训。免疫学的最新进展,杜克 大学,以获得博士学位(博士)在免疫学中。为了 达到这一目标,申请人将开始研究生院在9月。1993 并选择了将在此阶段完成的课程。 B。获得淋巴细胞和单核细胞领域的实验室专业知识 功能,特别是关于这些细胞在 类风湿性关节炎等疾病的异常免疫反应。在 为了实现这一目标,将在跨膜 蛋白多糖CD 44。CD 44及其配体透明质酸(HA)参与了 调节免疫应答的白细胞表面相互作用。 白细胞上CD 44各种亚型的差异表达, 可溶形式的CD 44的产生可能导致CD 44的能力, 调节CD 3-T细胞受体介导的T淋巴细胞活化, 调节HA与白细胞的细胞表面结合。的具体目标 阶段l的这一部分是:1。为了表征存在于 人外周血T淋巴细胞、B淋巴细胞和单核细胞 特别是在分子特征方面, HA与CD 44的结合。2.表征单克隆和多克隆抗体 与CD 44的特异性同种型和/或功能性表位结合的试剂 分子。 第二阶段的深入研究经验将利用这些试剂 以及获得的关于不同CD 44亚型在T细胞中的作用的知识, 淋巴细胞活化及其结合HA的能力,以研究调节 研究CD 44在肿瘤发病中的作用 类风湿性关节炎第二阶段的具体目标是:1.以限定 细胞外信号和细胞内分子事件, 调节CD 44与HA的结合并增强TCR介导的T细胞活化。2. 明确CD 44在免疫应答中的调节作用, 单个CD 44同种型的免疫介导功能。3.审查 类风湿性关节炎中的异常免疫应答利用 抗体试剂开发阶段土地获得的知识, 调节CD 44。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARC C. LEVESQUE其他文献

MARC C. LEVESQUE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARC C. LEVESQUE', 18)}}的其他基金

Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients
利妥昔单抗治疗肌炎患者的缓解和复发机制
  • 批准号:
    8522158
  • 财政年份:
    2010
  • 资助金额:
    $ 5.22万
  • 项目类别:
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients
利妥昔单抗治疗肌炎患者的缓解和复发机制
  • 批准号:
    8318804
  • 财政年份:
    2010
  • 资助金额:
    $ 5.22万
  • 项目类别:
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients
利妥昔单抗治疗肌炎患者的缓解和复发机制
  • 批准号:
    8146973
  • 财政年份:
    2010
  • 资助金额:
    $ 5.22万
  • 项目类别:
Mechanisms of Response and Relapse in Rituximab-treated Myositis Patients
利妥昔单抗治疗肌炎患者的缓解和复发机制
  • 批准号:
    8088402
  • 财政年份:
    2010
  • 资助金额:
    $ 5.22万
  • 项目类别:
Randomized observation study of biologic therapy for rheumatoid arthritis
类风湿性关节炎生物治疗的随机观察研究
  • 批准号:
    8040371
  • 财政年份:
    2010
  • 资助金额:
    $ 5.22万
  • 项目类别:
Randomized observation study of biologic therapy for rheumatoid arthritis
类风湿性关节炎生物治疗的随机观察研究
  • 批准号:
    7942942
  • 财政年份:
    2009
  • 资助金额:
    $ 5.22万
  • 项目类别:
Randomized observation study of biologic therapy for rheumatoid arthritis
类风湿性关节炎生物治疗的随机观察研究
  • 批准号:
    7856255
  • 财政年份:
    2009
  • 资助金额:
    $ 5.22万
  • 项目类别:
Prevention of Chronic Lymphocytic Leukemia (CLL)
预防慢性淋巴细胞白血病 (CLL)
  • 批准号:
    7490723
  • 财政年份:
    2007
  • 资助金额:
    $ 5.22万
  • 项目类别:
Prevention of Chronic Lymphocytic Leukemia (CLL)
预防慢性淋巴细胞白血病 (CLL)
  • 批准号:
    7263427
  • 财政年份:
    2007
  • 资助金额:
    $ 5.22万
  • 项目类别:
Human TNFa-Induced Pre-B Cell Bone Marrow Emigrants
人 TNFa 诱导的前 B 细胞骨髓移出
  • 批准号:
    7105129
  • 财政年份:
    2006
  • 资助金额:
    $ 5.22万
  • 项目类别:

相似海外基金

The molecular basis of T cell receptor cross-reactivity between MHC and MR1
MHC 和 MR1 之间 T 细胞受体交叉反应的分子基础
  • 批准号:
    DP240102905
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Discovery Projects
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23K28188
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
CAREER: Understanding the Impact of Dephosphorylation Kinetics and Adapter Specificity on Synthetic T Cell Receptor Signaling and Function
职业:了解去磷酸化动力学和接头特异性对合成 T 细胞受体信号传导和功能的影响
  • 批准号:
    2339172
  • 财政年份:
    2024
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Continuing Grant
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
预测癌症患者预后的特殊公共 T 细胞受体序列
  • 批准号:
    10577518
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Machine Learning of Disease Biomarkers from B and T cell Receptor Repertoires
来自 B 和 T 细胞受体库的疾病生物标志物的机器学习
  • 批准号:
    23H03498
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Impact of T cell receptor signaling on memory CD8+ T cell stemness
T 细胞受体信号传导对记忆 CD8 T 细胞干性的影响
  • 批准号:
    10676407
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
T cell receptor cross-reactivity and structural basis of virus immune escape
T细胞受体交叉反应性和病毒免疫逃逸的结构基础
  • 批准号:
    22KK0277
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy
使用体内新型免疫原策略生成 T 细胞受体模拟亲和试剂
  • 批准号:
    10599584
  • 财政年份:
    2023
  • 资助金额:
    $ 5.22万
  • 项目类别:
Mechanical regulation of T cell receptor and co-receptor responses in cancer immunotherapy
癌症免疫治疗中 T 细胞受体和辅助受体反应的机械调节
  • 批准号:
    10530023
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma
抑制 T 细胞受体信号转导治疗成人 T 细胞白血病淋巴瘤
  • 批准号:
    10684172
  • 财政年份:
    2022
  • 资助金额:
    $ 5.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了